시신경척수염 환자 수 분석과 예측(2026-2035년)

Global Neuromyelitis Optica Patient Population Analysis is projected to register a strong CAGR during the forecast period (2026-2035).

Neuromyelitis Optica Spectrum Disorder (NMOSD) is a rare autoimmune inflammatory disease of the central nervous system that primarily affects the optic nerves and spinal cord. The disease is characterized by recurrent episodes of optic neuritis, transverse myelitis, and brainstem inflammation, often resulting in permanent neurological disability if left untreated. Advances in antibody-based diagnostics have significantly improved disease recognition and differentiation from multiple sclerosis, leading to more accurate identification of patients worldwide. As innovative biologic therapies continue to enter the market, patient population analysis has become increasingly important for healthcare planning, clinical trial recruitment, market forecasting, and reimbursement decision-making.

Patient population analysis provides comprehensive insights into disease prevalence, incidence, diagnosed patient populations, demographic characteristics, antibody status, disease severity, regional distribution, and long-term epidemiological forecasts. These analyses enable pharmaceutical companies, biotechnology firms, healthcare providers, policymakers, researchers, and investors to evaluate market opportunities and optimize treatment strategies.

Market Drivers

Increasing Diagnostic Accuracy

One of the primary drivers of market growth is the widespread adoption of advanced diagnostic technologies, particularly highly sensitive AQP4 antibody assays and improved magnetic resonance imaging (MRI). These advances have significantly reduced diagnostic delays and improved differentiation between NMOSD and multiple sclerosis.

Earlier diagnosis enables more accurate patient identification, expanding epidemiological databases and supporting better long-term disease monitoring.

Growing Disease Awareness

Awareness among neurologists and healthcare providers has increased substantially following the publication of updated diagnostic criteria and the availability of targeted biologic therapies. Improved education initiatives and rare disease advocacy programs have contributed to earlier referrals and higher diagnosis rates worldwide.

Greater awareness continues to strengthen patient registry development and epidemiological research.

Expansion of Patient Registries

National and international rare disease registries are generating increasingly comprehensive data regarding patient demographics, disease progression, treatment patterns, and long-term outcomes.

These registries improve patient identification, facilitate clinical trial recruitment, support real-world evidence generation, and strengthen future population forecasting.

Rising Demand for Precision Medicine

The development of targeted therapies requires detailed understanding of patient subgroups based on antibody status, age, disease severity, and clinical phenotype.

Patient population analysis enables pharmaceutical companies to estimate eligible treatment populations and optimize commercialization strategies for precision therapies.

Market Restraints

Rare Disease Status

NMOSD remains a relatively uncommon neurological disorder, resulting in a limited global patient population and smaller epidemiological datasets compared with more common neurological diseases.

Regional Differences in Diagnosis

Access to antibody testing, specialist neurological care, and advanced diagnostic infrastructure varies considerably between developed and emerging markets, leading to underdiagnosis in certain regions.

Variability in Epidemiological Data

Differences in diagnostic criteria, registry coverage, healthcare reporting systems, and study methodologies may produce variability in prevalence and incidence estimates across countries.

Epidemiology and Patient Population Insights

Although NMOSD is a rare disease, improvements in diagnosis and awareness have resulted in increasing identification of patients worldwide.

Recent global epidemiological studies estimate that NMOSD prevalence ranges from approximately 0.07 to 10 cases per 100,000 population, while annual incidence ranges from approximately 0.03 to 0.88 cases per 100,000 population, depending on geographic region, ethnicity, and diagnostic methodology. The highest prevalence has been reported in Afro-Caribbean and certain Asian populations, whereas lower prevalence has generally been observed in White populations.

Women account for the majority of diagnosed cases, particularly among AQP4 antibody-positive patients, with female-to-male ratios frequently exceeding 8:1. Disease onset most commonly occurs during middle adulthood, although pediatric and late-onset cases are increasingly recognized.

The diagnosed patient population is expected to increase steadily throughout the forecast period as access to antibody testing expands, physician awareness improves, and rare disease surveillance programs become more comprehensive.

Technology and Segment Insights

The global NMOSD patient population analysis market can be segmented by disease subtype, antibody status, age group, gender, disease stage, data source, end user, and geography.

By disease subtype, the market includes AQP4 antibody-positive NMOSD, myelin oligodendrocyte glycoprotein (MOG)-associated disease, and seronegative NMOSD. AQP4-positive patients represent the largest diagnosed patient segment.

By antibody status, patient populations are categorized into AQP4-positive, MOG-positive, and double-seronegative groups, supporting personalized treatment selection and clinical research.

By age group, the market includes pediatric, adult, and elderly patient populations. Adult patients account for the largest proportion of diagnosed cases.

By disease stage, the market includes newly diagnosed patients, relapsing disease, stable disease, and advanced disability populations.

By data source, the market includes patient registries, hospital databases, electronic health records, laboratory databases, insurance claims, and population-based epidemiological studies.

By end user, the market serves pharmaceutical companies, biotechnology firms, healthcare providers, academic institutions, contract research organizations, government agencies, and healthcare consulting firms.

Technological advancements in artificial intelligence, predictive analytics, digital health platforms, biomarker research, and real-world evidence systems are enhancing patient identification, disease surveillance, and long-term epidemiological forecasting.

Regional Insights

North America remains the leading market for NMOSD patient population analysis due to advanced diagnostic infrastructure, widespread antibody testing, established patient registries, and extensive rare disease research programs.

Europe represents another significant market supported by collaborative neurological research networks, comprehensive healthcare systems, and expanding epidemiological surveillance initiatives.

Asia-Pacific is expected to witness the fastest growth during the forecast period owing to improving healthcare infrastructure, increasing access to antibody testing, rising awareness of autoimmune neurological disorders, and expanding clinical research activities. Countries including Japan, China, South Korea, and India continue to strengthen rare disease diagnosis and patient registry programs.

Latin America and the Middle East & Africa are gradually improving epidemiological surveillance through better diagnostic capabilities, expanding healthcare access, and participation in international research collaborations.

Competitive Landscape

The competitive landscape includes epidemiology research organizations, healthcare analytics providers, patient registry operators, pharmaceutical companies, biotechnology firms, academic research institutions, and healthcare consulting organizations.

Industry participants continue to invest in real-world evidence generation, digital epidemiology platforms, biomarker research, and advanced healthcare analytics. Strategic collaborations among pharmaceutical companies, academic centers, patient advocacy groups, and government agencies are improving patient identification and strengthening epidemiological research.

Growing adoption of targeted biologic therapies is also increasing demand for highly detailed patient segmentation and long-term population forecasting.

Future Outlook

The future NMOSD patient population analysis market is expected to be driven by continued expansion of antibody testing, increasing adoption of precision medicine, broader implementation of digital health technologies, and greater integration of artificial intelligence into epidemiological research.

Advances in genomic medicine, biomarker discovery, and real-world evidence platforms are expected to improve patient identification, refine disease classification, and enhance long-term forecasting accuracy.

As awareness continues to increase worldwide, more comprehensive patient databases will support clinical development, healthcare planning, reimbursement strategies, and commercialization of emerging therapies.

Conclusion

The global Neuromyelitis Optica patient population analysis market is poised for sustained growth through 2035, supported by expanding diagnostic capabilities, increasing disease awareness, growing investment in rare neurological disease research, and the rising adoption of targeted biologic therapies. While challenges related to underdiagnosis, regional variability, and limited epidemiological datasets remain, advances in antibody diagnostics, patient registries, artificial intelligence, and real-world evidence are expected to significantly enhance patient identification and long-term disease forecasting. These developments will strengthen clinical research, optimize healthcare resource allocation, and support the successful commercialization of innovative NMOSD therapies.

Key Benefits of this Report

• Insightful Analysis: Comprehensive evaluation of global NMOSD prevalence, incidence, diagnosed patient populations, and epidemiological trends.
• Competitive Landscape: Understand regional disease burden, demographic characteristics, and evolving patient registry initiatives.
• Market Drivers and Future Trends: Assess factors influencing patient identification, diagnosis rates, and future population growth.
• Actionable Recommendations: Support healthcare planning, clinical trial recruitment, commercialization strategies, and investment decisions.
• Caters to a Wide Audience: Suitable for pharmaceutical companies, biotechnology firms, healthcare providers, researchers, consultants, investors, and policymakers.

What Businesses Use Our Reports For

Patient population forecasting, epidemiological assessment, clinical trial planning, market opportunity evaluation, healthcare resource planning, rare disease strategy development, investment analysis, commercialization planning, and reimbursement assessment.

Report Coverage

• Historical data from 2021 to 2025, Base year 2025, and Forecast years from 2026 to 2035
• Global, regional, and country-level patient population analysis and forecasts
• Prevalence, incidence, diagnosed patient population, antibody status, and demographic segmentation
• Disease-stage assessment, epidemiological trends, and regional burden analysis
• Competitive intelligence, patient registry evaluation, and future market opportunity outlook.

TABLE OF CONTENTS

1. Executive Summary

• 1.1 Market Snapshot
• 1.2 Key Epidemiology Insights
• 1.3 Patient Population Overview
• 1.4 Key Growth Drivers and Challenges
• 1.5 Treatment Landscape Highlights
• 1.6 Competitive Overview
• 1.7 Future Outlook

2. Disease & Epidemiology Analysis

• 2.1 Overview of Neuromyelitis Optica
  • 2.1.1 Disease Definition
  • 2.1.2 Historical Evolution and Classification
  • 2.1.3 Pathophysiology
  • 2.1.4 Disease Burden
• 2.2 Disease Classification
  • 2.2.1 AQP4-IgG Positive Neuromyelitis Optica Spectrum Disorder (NMOSD)
  • 2.2.2 AQP4-IgG Negative NMOSD
  • 2.2.3 MOG Antibody-Associated Disease (MOGAD) Differential Diagnosis
  • 2.2.4 Seronegative NMOSD
• 2.3 Etiology and Risk Factors
  • 2.3.1 Genetic Factors
  • 2.3.2 Autoimmune Associations
  • 2.3.3 Environmental Factors
  • 2.3.4 Gender and Age Distribution
• 2.4 Clinical Manifestations
  • 2.4.1 Optic Neuritis
  • 2.4.2 Acute Myelitis
  • 2.4.3 Area Postrema Syndrome
  • 2.4.4 Brainstem and Cerebral Syndromes
• 2.5 Diagnostic Criteria and Biomarkers
  • 2.5.1 International Consensus Diagnostic Criteria
  • 2.5.2 Aquaporin-4 Antibody Testing
  • 2.5.3 MOG Antibody Testing
  • 2.5.4 Imaging and Laboratory Assessment
• 2.6 Global Epidemiology Analysis
  • 2.6.1 Prevalence Analysis
  • 2.6.2 Incidence Analysis
  • 2.6.3 Diagnosed Patient Population
  • 2.6.4 Treated Patient Population
  • 2.6.5 Gender-Based Patient Population
  • 2.6.6 Age-Based Patient Population
  • 2.6.7 AQP4-IgG Positive Patient Population
  • 2.6.8 AQP4-IgG Negative Patient Population
  • 2.6.9 Relapsing versus Monophasic Disease Population

3. Market Dynamics

• 3.1 Market Drivers
  • 3.1.1 Increasing Disease Awareness
  • 3.1.2 Improved Diagnostic Capabilities
  • 3.1.3 Expansion of Targeted Biologic Therapies
  • 3.1.4 Growing Healthcare Expenditure
• 3.2 Market Restraints
  • 3.2.1 Rare Disease Patient Pool
  • 3.2.2 High Treatment Costs
  • 3.2.3 Delayed Diagnosis
  • 3.2.4 Limited Access in Emerging Markets
• 3.3 Market Opportunities
  • 3.3.1 Complement Pathway Inhibitors
  • 3.3.2 FcRn Inhibitors
  • 3.3.3 Personalized Medicine Approaches
  • 3.3.4 Emerging Biomarkers
• 3.4 Porter's Five Forces Analysis
• 3.5 PESTLE Analysis

4. Commercial & Market Access

• 4.1 Reimbursement Landscape
• 4.2 Pricing Analysis of Approved Therapies
• 4.3 Health Technology Assessment Trends
• 4.4 Market Access Challenges
• 4.5 Rare Disease Funding Programs
• 4.6 Patient Assistance Programs
• 4.7 Distribution and Supply Chain Trends

5. Innovation & Pipeline Landscape

• 5.1 Overview of Pipeline Landscape
• 5.2 Pipeline Analysis by Development Stage
  • 5.2.1 Phase I
  • 5.2.2 Phase II
  • 5.2.3 Phase III
• 5.3 Pipeline Analysis by Mechanism of Action
  • 5.3.1 Complement Inhibitors
  • 5.3.2 Anti-CD19 Therapies
  • 5.3.3 IL-6 Receptor Inhibitors
  • 5.3.4 FcRn Inhibitors
  • 5.3.5 B-cell Targeting Therapies
  • 5.3.6 Novel Immunomodulators
• 5.4 Pipeline Analysis by Modality
  • 5.4.1 Monoclonal Antibodies
  • 5.4.2 Recombinant Proteins
  • 5.4.3 Small Molecules
  • 5.4.4 Cell-Based Therapies
• 5.5 Clinical Trial Landscape
• 5.6 Innovation Trends
• 5.7 Emerging Technologies and Future Therapies

6. Treatment Landscape

• 6.1 Current Treatment Algorithm
• 6.2 Acute Attack Management
  • 6.2.1 Corticosteroids
  • 6.2.2 Plasma Exchange
  • 6.2.3 Intravenous Immunoglobulin
• 6.3 Maintenance Therapy
  • 6.3.1 Complement Inhibitors
  • 6.3.2 Anti-CD19 Therapies
  • 6.3.3 IL-6 Receptor Inhibitors
  • 6.3.4 B-cell Depleting Therapies
  • 6.3.5 Immunosuppressive Agents
• 6.4 Approved Therapies Overview
  • 6.4.1 Soliris (Eculizumab)
  • 6.4.2 Ultomiris (Ravulizumab-cwvz)
  • 6.4.3 Uplizna (Inebilizumab-cdon)
  • 6.4.4 Enspryng (Satralizumab-mwge)
• 6.5 Unmet Needs and Treatment Gaps

7. Global Neuromyelitis Optica Patient Population Analysis Size & Forecast

• 7.1 Market Overview
• 7.2 Historical Market Size Analysis
• 7.3 Forecast Market Size Analysis
• 7.4 Market Growth Rate Analysis
• 7.5 Epidemiology-Based Market Forecast
• 7.6 Treatment Adoption Forecast
• 7.7 Scenario Analysis

8. Global Neuromyelitis Optica Patient Population Analysis Segmentation

• 8.1 By Treatment Type
  • 8.1.1 Anti-CD19 Therapies
  • 8.1.2 IL-6 Receptor Inhibitors
  • 8.1.3 Immunosuppressants
  • 8.1.4 Others
• 8.2 By Disease Type
  • 8.2.1 AQP4-IgG Positive NMOSD
  • 8.2.2 AQP4-IgG Negative NMOSD
• 8.3 By Gender
  • 8.3.1 Female
  • 8.3.2 Male
• 8.4 By Age Groups
  • 8.4.1 Pediatric
  • 8.4.2 Adults
  • 8.4.3 Elderly
• 8.5 By Care Setting
  • 8.5.1 Hospitals
  • 8.5.2 Specialty Clinics
  • 8.5.3 Others

9. Geographical Analysis

• 9.1 North America
  • 9.1.1 Market Size and Growth
  • 9.1.2 Epidemiology Trends
  • 9.1.3 Regulatory Overview
  • 9.1.4 Competitive Intensity
• 9.2 Europe
  • 9.2.1 Market Size and Growth
  • 9.2.2 Epidemiology Trends
  • 9.2.3 Regulatory Overview
  • 9.2.4 Competitive Intensity
• 9.3 Asia-Pacific
  • 9.3.1 Market Size and Growth
  • 9.3.2 Epidemiology Trends
  • 9.3.3 Regulatory Overview
  • 9.3.4 Competitive Intensity
• 9.4 Latin America
  • 9.4.1 Market Size and Growth
  • 9.4.2 Epidemiology Trends
  • 9.4.3 Regulatory Overview
  • 9.4.4 Competitive Intensity
• 9.5 Middle East & Africa
  • 9.5.1 Market Size and Growth
  • 9.5.2 Epidemiology Trends
  • 9.5.3 Regulatory Overview
  • 9.5.4 Competitive Intensity

10. Key Countries Analysis

• 10.1 United States
• 10.2 Canada
• 10.3 Germany
• 10.4 United Kingdom
• 10.5 France
• 10.6 Italy
• 10.7 Spain
• 10.8 China
• 10.9 Japan
• 10.10 India
• 10.11 South Korea
• 10.12 Australia
• 10.13 Brazil
• 10.14 Mexico
• 10.15 Saudi Arabia
• 10.16 South Africa

11. Regulatory & Policy Landscape

• 11.1 Regulatory Overview for Rare Autoimmune Diseases
• 11.2 United States FDA Framework
• 11.3 European Medicines Agency (EMA) Framework
• 11.4 Japan PMDA Framework
• 11.5 India CDSCO Framework
• 11.6 China NMPA Framework
• 11.7 Orphan Drug Regulations
• 11.8 Accelerated Approval Pathways
• 11.9 Pharmacovigilance Requirements

12. Competitive Landscape

• 12.1 Market Share Analysis
• 12.2 Competitive Benchmarking
• 12.3 Product Portfolio Analysis
• 12.4 Pipeline Competitiveness Analysis
• 12.5 Strategic Collaborations and Licensing Agreements
• 12.6 Mergers and Acquisitions
• 12.7 Recent Developments

13. Company Profiles

• 13.1 Alexion Pharmaceuticals
  • 13.1.1 Company Overview
  • 13.1.2 Approved Products: Soliris (Eculizumab), Ultomiris (Ravulizumab-cwvz)
  • 13.1.3 Key Indications
  • 13.1.4 Pipeline Overview
• 13.2 AstraZeneca
  • 13.2.1 Company Overview
  • 13.2.2 Rare Disease Portfolio
  • 13.2.3 Key Indications
  • 13.2.4 Pipeline Overview
• 13.3 Amgen Inc.
  • 13.3.1 Company Overview
  • 13.3.2 Approved Product: Uplizna (Inebilizumab-cdon)
  • 13.3.3 Key Indications
  • 13.3.4 Pipeline Overview
• 13.4 Roche Holding AG
  • 13.4.1 Company Overview
  • 13.4.2 Approved Product: Enspryng (Satralizumab)
  • 13.4.3 Key Indications
  • 13.4.4 Pipeline Overview
• 13.5 Chugai Pharmaceutical Co., Ltd.
  • 13.5.1 Company Overview
  • 13.5.2 Approved Product: Enspryng (Satralizumab)
  • 13.5.3 Key Indications
  • 13.5.4 Pipeline Overview
• 13.6 Tanabe Pharma Corporation
  • 13.6.1 Company Overview
  • 13.6.2 Immunology Portfolio
  • 13.6.3 Key Indications
  • 13.6.4 Pipeline Overview
• 13.7 argenx SE
  • 13.7.1 Company Overview
  • 13.7.2 FcRn Inhibitor Portfolio
  • 13.7.3 Key Indications
  • 13.7.4 Pipeline Overview
• 13.8 Dianthus Therapeutics, Inc.
  • 13.8.1 Company Overview
  • 13.8.2 Complement Pathway Programs
  • 13.8.3 Key Indications
  • 13.8.4 Pipeline Overview
• 13.9 Novartis AG
  • 13.9.1 Company Overview
  • 13.9.2 Immunology Portfolio
  • 13.9.3 Key Indications
  • 13.9.4 Pipeline Overview
• 13.10 Kyverna Therapeutics, Inc.
  • 13.10.1 Company Overview
  • 13.10.2 Autoimmune Disease Programs
  • 13.10.3 Key Indications
  • 13.10.4 Pipeline Overview

14. Future Outlook

• 14.1 Future Epidemiology Trends
• 14.2 Emerging Therapeutic Paradigms
• 14.3 Innovation Outlook
• 14.4 Market Growth Opportunities
• 14.5 Long-Term Forecast Scenario

15. Methodology

• 15.1 Research Objectives
• 15.2 Secondary Research Methodology
• 15.3 Primary Research Methodology
• 15.4 Epidemiology Modeling Approach
• 15.5 Market Estimation and Forecasting Methodology
• 15.6 Data Validation and Triangulation
• 15.7 Assumptions and Limitations